http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
General and Facile Coating of Single Cells via Mild Reduction
Kim, Hyunbum,Shin, Kwangsoo,Park, Ok Kyu,Choi, Daheui,Kim, Hwan D.,Baik, Seungmin,Lee, Soo Hong,Kwon, Seung-Hae,Yarema, Kevin J.,Hong, Jinkee,Hyeon, Taeghwan,Hwang, Nathaniel S. American Chemical Society 2018 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.140 No.4
<P>Cell surface modification has been extensively studied to enhance the efficacy of cell therapy. Still, general accessibility and versatility are remaining challenges to meet the increasing demand for cell-based therapy. Herein, we present a facile and universal cell surface modification method that involves mild reduction of disulfide bonds in cell membrane protein to thiol groups. The reduced cells are successfully coated with biomolecules, polymers, and nanoparticles for an assortment of applications, including rapid cell assembly, in vivo cell monitoring, and localized cell-based drug delivery. No adverse effect on cellular morphology, viability, proliferation, and metabolism is observed. Furthermore, simultaneous coating with polyethylene glycol and dexamethasone-loaded nanoparticles facilitates enhanced cellular activities in mice, overcoming immune rejection.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jacsat/2018/jacsat.2018.140.issue-4/jacs.7b08440/production/images/medium/ja-2017-08440m_0006.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/ja7b08440'>ACS Electronic Supporting Info</A></P>
Two recessive intermediate Charcot‐Marie‐Tooth patients with <i>GDAP1</i> mutations
Chung, Ki W.,Hyun, Young S.,Lee, Hae J.,Jung, Hwa‐,Kyoung,Koo, Heasoo,Yoo, Jeong H.,Kim, Sang‐,Beom,Park, Chan I.,Kim, Han N.,Choi, Byung‐,Ok Blackwell Publishing Ltd 2011 Journal of the peripheral nervous system Vol.16 No.2
<P>Various phenotypes have been reported in Charcot‐Marie‐Tooth (CMT) disease carrying mutations in the <I>ganglioside‐induced differentiation‐associated protein 1</I> (<I>GDAP1</I>) gene. Here, we report two recessive intermediate Charcot‐Marie‐Tooth (RI‐CMT) patients with <I>GDAP1</I> missense mutations: a His256Arg homozygous mutation (c.767A>G + c.767A>G) and compound mutations of heterozygous Pro111His (c.332C>A) and Val219Gly (c.656T>G). The Pro111His and Val219Gly are unreported mutations, but the His256Arg was previously reported. In both patients, histopathological findings showed well‐documented features of mixed demyelinating and axonal neuropathies, and nerve conduction velocities fall in the intermediate range. In addition, the patterns of fatty substitutions in leg magnetic resonance imaging (MRI) were different by the mutation sites within the same <I>GDAP1</I> gene.</P>
Jeong, Ju Hwan,Kim, Eun-Ha,Lloren, Khristine Kaith S.,Kwon, Jin Jung,Kwon, Hyeok-il,Ahn, Su Jeong,Kim, Young-Il,Choi, Won-Suk,Si, Young-Jae,Lee, Ok-Jun,Han, Hae Jung,Baek, Yun Hee,Song, Min-Suk,Choi, Elsevier 2019 Vaccine Vol.37 No.3
<P><B>Abstract</B></P> <P>Because H5N1 influenza viruses continuously threaten the public health, the WHO has prepared various clades of H5N1 mock-up vaccines as one of the measures for pandemic preparedness. The recent worldwide outbreak of H5Nx virus which belongs to clade 2.3.4.4 and of which H5N6 subtype belongs and already caused human infection also increases the need of pandemic vaccine for such novel emerging viruses. In this study, we evaluated the protective efficacy and immunogenicity of an egg-based and inactivated whole-virus H5N8 (IDCDC-RG43A) developed by CDC containing HA and NA gene of the parent virus A/gyrfalcon/Washington/41088-6/2014. Mice vaccinated two times elicited low to moderate antibody titer in varying amount of antigen doses against the homologous H5N8 vaccine virus and heterologous intra–clade 2.3.4.4 H5N6 (A/Sichuan/26221/2014) virus. Mice immunized with at least 3.0 µg/dose of IDCDC-RG43A with aluminum hydroxide adjuvant were completely protected from lethal challenge with the mouse-adapted H5N8 (A/Environment/Korea/ma468/2015, maH5N8) as well as cleared the viral replication in tissues including lung, brain, spleen, and kidney. Vaccinated ferrets induced high antibody titers against clade 2.3.4.4 H5N8/H5N6 viruses and the antibody showed high cross-reactivity to clade 2.2 H5N1 but not to clade 1 and 2.3.4 viruses as measured by hemagglutinin inhibition and serum neutralization assays. Furthermore, administration of the vaccine in ferrets resulted in attenuation of clinical disease signs and virus spread to peripheral organs including lung, spleen, and kidney from high dose challenge with maH5N8 virus. The protective and immunogenic characteristic of the candidate vaccine are essential attributes to be considered for further clinical trials as a pre-pandemic vaccine for a potential pandemic virus.</P>